23rd International AIDS Conference (AIDS 2020): second reports

28 August 2020. Related: Conference reports, World AIDS 23 Virtual 2020, Conference index.

6 – 10 July 2020, virtual meeting (was San Francisco and Santa Barbara).

The conference website is now available as an open access resource that no longer needs registration details.

Abstracts are now online, although the portal is still not always easy to navigate.

Many presentations are also online, but many also have withheld permission for these to be posted online. Perhaps these should not have been accepted for a virtual conference.

https://cattendee.abstractsonline.com/meeting/9289

The following reports are included in this issue of HTB.

• Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing

• Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020

• Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain

• Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study

• Paediatric dolutegravir dosing: AIDS 2020

• COVID-19 outcomes in HIV positive people in two large US cohorts

• AIDS 2020: virtual content now available free and on-demand

• Pathways to an HIV cure: online presentations